Study of Immunotherapies Focusing on Vaccines for Parkinson's: a scientific and technological prospection
DOI:
https://doi.org/10.9771/cp.v19i2.65190Keywords:
Neurodegenerative Diseases, Therapeutics, BLOCKCHAIN. VACCINE. SUPPLYCHAINAbstract
Parkinson's disease is a neurodegenerative disease characterized by the loss of dopaminergic neurons, with a major impact on patients' quality of life. This study investigated the development of vaccine-based immunotherapies for the disease, using the ScienceDirect and PubMed databases for scientific prospecting and WIPO, Google Patents and INPI for technological prospecting. In the scientific prospecting, four monoclonal antibodies and two immunotherapeutic technologies in the clinical phase were identified. In the technological prospecting, the USA and Japan led with the highest number of active patents. In Brazil, no related publications or patents were found. From the WIPO and Google Patents databases, only six relevant patents were located. The results highlight the need for innovative strategies, such as the analysis of genes, proteins and immune cells, to develop effective and safe immunotherapies, reinforcing the importance of scientific and technological research in the advancement of therapies against Parkinson's.
Downloads
References
ANTONINI, A. et al. Immunization therapies for Parkinson’s disease: state of the art and considerations for future clinical trials. Expert Opinion on Investigational Drugs, v. 29, n. 7, p. 685-695, 2020.
BALESTRINO, R.; SCHAPIRA, A. H. V. Parkinson disease. European Journal of Neurology, v. 27, n. 1, p. 27-42, 2020.
BRUNDIN, P.; DAVE, K. D.; KORDOWER, J. H. Therapeutic approaches to target alpha-synuclein pathology. Experimental Neurology, v. 298, p. 225-235, 2017.
CAO, C. et al. P3‐531: The rationale of mutated amyloid beta sensitized dendritic cells as a therapeutic vaccine for alzheimer's disease. Alzheimer's & Dementia, v. 15, p. P1174-P1174, 2019.
CAO, Chuanhai; LIN, Xiaoyang. Methods, Antibodies, and Vaccines Utilizing Epitopes of Alpha Synuclein for Treatment of Parkinsons Disease. Estados Unidos, US20170196948A1, 2017.
CHATTERJEE, D.; KORDOWER, J. H. Immunotherapy in Parkinson’s disease: Current status and future directions. Neurobiology of Disease, v. 132, p. 104587, 2019.
CHURCH, F. C. Treatment options for motor and non-motor symptoms of Parkinson’s disease. Biomolecules, v. 11, n. 4, p. 612, 2021.
DAVODABADI, F. et al. Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches. Journal of Controlled Release, v. 349, p. 844-875, 2022.
DUWA, R.; JEONG, J. H.; YOOK, S. Development of immunotherapy and nanoparticles-based strategies for the treatment of Parkinson’s disease. Journal of Pharmaceutical Investigation, v. 51, p. 465-481, 2021.
EKMARK-LEWÉN, S. et al. Reduction of brain stem pathology and transient amelioration of early cognitive symptoms in transgenic mice treated with a monoclonal antibody against α-synuclein oligomers/protofibrils. Aging Brain, v. 4, p. 100086, 2023.
EL-AGNAF, O. et al. Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy. Neurobiology of Disease, v. 104, p. 85-96, 2017.
FLEMING, S. M.; DAVIS, A.; SIMONS, E. Targeting alpha-synuclein via the immune system in Parkinson's disease: current vaccine therapies. Neuropharmacology, v. 202, p. 108870, 2022.
GAMES, D. et al. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models. Journal of Neuroscience, v. 34, n. 28, p. 9441-9454, 2014.
HAENG, Joon Rhee et al. Vaccine production based on flagellin vaccine adjuvants that induce production of antibodies that recognize conformational isomers and applications thereof. Japão, JP2021020960A, 2021.
HENDERSON, M. X.; TROJANOWSKI, J. Q.; LEE, V. M.-Y. α-Synuclein pathology in Parkinson’s disease and related α-synucleinopathies. Neuroscience Letters, v. 709, p. 134316, 2019.
HULL, M. et al. Long-Term extensions of randomized vaccination trials of ACC-001 and QS-21 in mild to moderate alzheimer's disease. Current Alzheimer Research, v. 14, n. 7, p. 696-708, 2017.
JASROTIA, R. et al. Nanotechnology based vaccines: Cervical cancer management and perspectives. Journal of Drug Delivery Science and Technology, v. 71, p. 103351, 2022.
KHAN, M. D. S. S.; CATANZARO, J. A. SOLVx therapeutics vaccine–Activate T-cell immunity using broad surveillance epitope strategy against mutant strains SARS-COV2. Biomedicine & Pharmacotherapy, v. 152, p. 113212, 2022.
KUDRNA, J. J.; UGEN, K. E. Gene-based vaccines and immunotherapeutic strategies against neurodegenerative diseases: Potential utility and limitations. Human Vaccines & Immunotherapeutics, v. 11, n. 8, p. 1921-1926, 2015.
LACOSTA, A. M. et al. Safety, tolerability and immunogenicity of an active anti-Aβ 40 vaccine (ABvac40) in patients with Alzheimer’s disease: A randomised, double-blind, placebo-controlled, phase i trial. Alzheimer's Research & Therapy, v. 10, p. 1-13, 2018.
LANG, A. E. et al. Trial of cinpanemab in early Parkinson’s disease. New England Journal of Medicine, v. 387, n. 5, p. 408-420, 2022.
MANDLER, M. V. E. et al. Next-generation active immunization approach for synucleinopathies: implications for Parkinson’s disease clinical trials. Acta Neuropathologica, v. 127, p. 861-879, 2014.
MOCHIZUKI, H.; CHOONG, C. J.; MASLIAH, E. A refined concept: α-synuclein dysregulation disease. Neurochemistry International, v. 119, p. 84-96, 2018.
NOVAK P. et al. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 1 trial. The Lancet Neurology, v. 16, n. 2, p. 123-134, 2017.
OBESO, J. A. et al. Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy. Movement Disorders, v. 32, n. 9, p. 1264-1310, 2017.
OLSON, K. E. et al. Safety, tolerability, and immune-biomarker profiling for year-long sargramostim treatment of Parkinson's disease. EBioMedicine, v. 67, 2021.
PAGANO, G. et al. Trial of prasinezumab in early-stage Parkinson’s disease. New England Journal of Medicine, v. 387, n. 5, p. 421-432, 2022.
PULENDRAN, B.; DAVIS, M. M. The science and medicine of human immunology. Science, v. 369, n. 6511, p. eaay4014, 2020.
REN, X. et al. Exosomal DNA aptamer targeting α-synuclein aggregates reduced neuropathological deficits in a mouse Parkinson’s disease model. Molecular Therapy-Nucleic Acids, v. 17, p. 726-740, 2019.
SENGUPTA, U.; KAYED, R. Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases. Progress in Neurobiology, v. 214, p. 102270, 2022.
SPENCER, B. et al. ESCRT-mediated uptake and degradation of brain-targeted α-synuclein single chain antibody attenuates neuronal degeneration in vivo. Molecular Therapy, v. 22, n. 10, p. 1.753-1.767, 2014.
TROIANO, G.; NARDI, A. Vaccine hesitancy in the era of COVID-19. Public Health, v. 194, p. 245-251, 2021.
WEIHOFEN, A. et al. Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models. Neurobiology of Disease, v. 124, p. 276-288, 2019.
WILLIAMS, G. P. et al. Unaltered T cell responses to common antigens in individuals with Parkinson's disease. Journal of the Neurological Sciences, v. 444, p. 120510, 2023.
WILLIAMS-GRAY, C. H.; WORTH, P. F. Parkinson's disease. Medicine, v. 44, n. 9, p. 542-546, 2016.
ZAMAN, R. U. et al. Preclinical evaluation of a microparticle-based transdermal vaccine patch against metastatic breast cancer. International Journal of Pharmaceutics, v. 627, p. 122249, 2022.
ZELLA, S. M. A. et al. Emerging immunotherapies for Parkinson disease. Neurology and Therapy, v. 8, p. 29-44, 2019.
ZHENG, Y. et al. Novel DNA aptamers for Parkinson’s disease treatment inhibit α-synuclein aggregation and facilitate its degradation. Molecular Therapy-Nucleic Acids, v. 11, p. 228-242, 2018.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Cadernos de Prospecção
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
O autor declara que: - Todos os autores foram nomeados. - Está submetendo o manuscrito com o consentimento dos outros autores. - Caso o trabalho submetido tiver sido contratado por algum empregador, tem o consentimento do referido empregador. - Os autores estão cientes de que é condição de publicação que os manuscritos submetidos a esta revista não tenham sido publicados anteriormente e não sejam submetidos ou publicados simultaneamente em outro periódico sem prévia autorização do Conselho Editorial. - Os autores concordam que o seu artigo ou parte dele possa ser distribuído e/ou reproduzido por qualquer forma, incluindo traduções, desde que sejam citados de modo completo esta revista e os autores do manuscrito. - Revista Cadernos de Prospecção está licenciado com uma Licença Creative Commons Attribution 4.0. Esta licença permite que outros remixem, adaptem e criem a partir do seu trabalho para fins não comerciais, e embora os novos trabalhos tenham de lhe atribuir o devido crédito e não possam ser usados para fins comerciais, os usuários não têm de licenciar esses trabalhos derivados sob os mesmos termos.
Este obra está licenciado com uma Licença Creative Commons Atribuição 4.0 Internacional.
